Phenotyping Adverse Drug Reactions: Statin-Related Myotoxicity

It is unclear the extent to which best practices for phenotyping disease states from electronic medical records (EMRs) translate to phenotyping adverse drug events. Here we use statin-induced myotoxicity as a case study to identify best practices in this area. We compared multiple phenotyping algorithms using administrative codes, laboratory measurements, and full-text keyword matching to identify statin-related myopathy from EMRs. Manual review of 300 deidentified EMRs with exposure to at least one statin, created a gold standard set of 124 cases and 176 controls. We tested algorithms using ICD-9 billing codes, laboratory measurements of creatine kinase (CK) and keyword searches of clinical notes and allergy lists. The combined keyword algorithms produced were the most accurate (PPV=86%, NPV=91%). Unlike in most disease phenotyping algorithms, addition of ICD9 codes or laboratory data did not appreciably increase algorithm accuracy. We conclude that phenotype algorithms for adverse drug events should consider text based approaches.

[1]  D. Voora,et al.  Phenotype Standardization for Statin-Induced Myotoxicity , 2014, Clinical pharmacology and therapeutics.

[2]  M. Pirmohamed,et al.  Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink , 2014, British journal of clinical pharmacology.

[3]  M. Pirmohamed,et al.  SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink , 2013, Clinical pharmacology and therapeutics.

[4]  B. Duncan,et al.  Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patients. , 2013, International journal of cardiology.

[5]  M. Hirai,et al.  Development of a detection algorithm for statin‐induced myopathy using electronic medical records , 2013, Journal of clinical pharmacy and therapeutics.

[6]  Melissa A. Basford,et al.  Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. , 2013, Journal of the American Medical Informatics Association : JAMIA.

[7]  Alexander Turchin,et al.  Accuracy of Electronically Reported “Meaningful Use” Clinical Quality Measures , 2013, Annals of Internal Medicine.

[8]  Xu Han,et al.  Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions , 2012, PLoS Comput. Biol..

[9]  S. Heckbert,et al.  Use of administrative data to estimate the incidence of statin-related rhabdomyolysis. , 2012, JAMA.

[10]  I. Kullo,et al.  ASSOCIATION OF A POLYMORPHISM IN SLCO1B1 WITH STATIN-INDUCED MYALGIAS, MYOSITIS AND MYOPATHY: AN ELECTRONIC MEDICAL RECORD BASED PHARMACOGENETIC STUDY , 2011 .

[11]  Randolph A. Miller,et al.  Research Paper: Evaluation of a Method to Identify and Categorize Section Headers in Clinical Documents , 2009, J. Am. Medical Informatics Assoc..

[12]  Terrie Kitchner,et al.  Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity. , 2009, Preventive cardiology.

[13]  D. Roden,et al.  Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.

[14]  P. Thompson,et al.  An assessment of statin safety by muscle experts. , 2006, The American journal of cardiology.

[15]  Alexander Turchin,et al.  Structured vs. unstructured: factors affecting adverse drug reaction documentation in an EMR repository. , 2011, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[16]  Kevin B. Johnson,et al.  Application of information technology: MedEx: a medication information extraction system for clinical narratives , 2010, J. Am. Medical Informatics Assoc..